Skip to content
Scopia

AI Impact Analytics

Measure Whether Your AI Investment Actually Works

You've invested €100,000+ in AI-assisted polyp detection. But do you know if it's actually improving your unit's quality?

AI Impact — Dr. Example
Low dependency
AI On
0%
ADR
AI Off
0%
ADR
Lift
0
AI uplift
Skill
0
Growth
Building real skills — unaided ADR improving faster than AI lift

The Problem

€100K+ Invested in CADe — But No Independent Measurement

Most units that deploy GI Genius, CAD EYE, or ENDO-AID have no way to answer these critical questions:

Does ADR actually improve with AI on?
Does each endoscopist benefit equally?
What happens when AI is turned off?
Is there a deskilling risk?

Emerging Risk

The Deskilling Problem

A 2025 Lancet Gastroenterology & Hepatology study found that endoscopists' ADR dropped by 6 percentage points when AI was turned off — suggesting dependency, not genuine skill improvement.

Without independent monitoring, you won't know if your team is building real skills or relying on AI as a crutch.

ADR When AI Is Turned Off

With AI 0%
Without AI (same endoscopists) 0%
-6 pp Lancet GH 2025

The Solution

Independent AI Impact Measurement

Scopia measures AI impact independently — no vendor bias, no guesswork.

AI-on vs. AI-off Comparison

Compare ADR and other quality indicators with AI enabled versus disabled — per endoscopist. See the real uplift, not just vendor claims.

Per-Endoscopist Analytics

Not every endoscopist benefits equally from CADe. Identify who gains the most and who may need additional training.

Vendor-Neutral

Works with GI Genius, CAD EYE, ENDO-AID, and any other CADe system. Scopia doesn't sell AI — we measure if AI works.

Deskilling Detection

Longitudinal tracking reveals whether endoscopists maintain their skills independently. Get early warnings when AI dependency develops.

Who Benefits

Proof for Every Stakeholder

For Hospitals

Proof that your €100K+ investment is paying off. Evidence-based ROI reporting for hospital leadership and procurement reviews.

For AI Vendors

Independent real-world evidence for regulatory submissions and sales materials. Third-party validation is more credible than internal data.

For Screening Programs

Data-driven decisions on AI deployment. Understand which units benefit most and where training should be prioritised.

The Only Independent AI Quality Measurement in Europe

No AI vendor can objectively measure their own impact
No EHR system tracks AI-on vs. AI-off quality
Scopia is vendor-neutral and designed for exactly this

See AI Impact Analytics in Action

Book a 15-minute demo and see how Scopia measures the real impact of your CADe investment.